Rimegepant
Rimegepant is a CGRP receptor blocker used in adults to treat migraine attacks as they happen and to help prevent episodic migraine.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Rimegepant (Nurtec ODT) blocks the receptor for CGRP, a molecule involved in migraine, and is approved in adults to stop a migraine attack and to help prevent episodic migraine. A relatively new medicine, it is often used when triptans, the usual first choice, have not worked or are not a good fit. Most people tolerate it well; nausea is the most common complaint, and stomach pain or indigestion shows up more with preventive use. Watch for a serious allergic reaction (trouble breathing, swelling, severe rash), even days after a dose, and call your prescriber about new high blood pressure or painful color changes in fingers or toes (Raynaud’s phenomenon).
Clinical pearls
- Open the blister just before use and let the tablet melt on or under your tongue, with no water needed.
- Drugs that slow or speed its breakdown (CYP3A4 inhibitors or inducers) can push levels too high or blunt its effect.
- With amiodarone, cyclosporine, quinidine, ranolazine or a moderate CYP3A4 inhibitor, avoid a second dose within 48 hours.
- High blood pressure was mostly reported within the first week, so checking a home reading early on is sensible.
Patient information guide A plain-language walkthrough of Rimegepant, written from its FDA label.
What Rimegepant is used for
▾
Rimegepant is used in adults for migraine.
- Nurtec ODT (oral orally disintegrating tablet) treats migraine attacks, with or without aura, as they occur.
- Nurtec ODT also helps prevent episodic migraine.
How Rimegepant works
▾
Rimegepant is a CGRP receptor antagonist. It blocks the receptor for calcitonin gene-related peptide, a molecule tied to migraine. The label notes that how this action produces its clinical effect is not known.
Rimegepant dosage
▾
Nurtec ODT is taken by mouth and dissolves on or under the tongue, with no water needed.
- For a migraine attack: taken as needed. The label says the maximum in 24 hours is one dose, and safety of more than 18 doses in 30 days has not been established.
- For prevention: taken every other day.
- It can be taken with or without food.
Use the tablet right after opening the blister pack. Follow your prescriber's directions.
Dosing details from the FDA-approved label
From the Rimegepant prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Acute treatment of migraine
- 75 mg taken orally, as needed
- Maximum: The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established.
- Can be taken with or without food
- Preventive treatment of episodic migraine
- 75 mg taken orally every other day
- Can be taken with or without food
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed. ( 2.1 ) • The safety of using more than 18 doses in a 30-day period has not been established. ( 2.1 ) • Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day. ( 2.2 ) • The maximum dose in a 24-hour period is 75 mg. ( 2.1 ) • NURTEC ODT can be taken with or without food. ( 2.1 , 2.2 ) 2.1 Recommended Dosing for Acute Treatment of Migraine The recommended dose of NURTEC ODT is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established. NURTEC ODT can be taken with or without food [see Clinical Pharmacology (12.3) ] . 2.2 Recommended Dosing for Preventive Treatment of Episodic Migraine The recommended dosage of NURTEC ODT is 75 mg taken orally every other day , with or without food . 2.3 Administration Information Instruct the patient on the following administration instructions: • Use dry hands when opening the blister pack. • Peel back the foil covering of one blister and gently remove the orally disintegrating tablet (ODT). Do not push the ODT through the foil. • As soon as the blister is opened, remove the ODT and place on the tongue; alternatively, the ODT may be placed under the tongue. • The ODT will disintegrate in saliva so that it can be swallowed without additional liquid. • Take the ODT immediately after opening the blister pack. Do not store the ODT outside the blister pack for future use. 2.4 Concomitant Administration with Strong or Moderate CYP3A4 Inhibitors Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . 2.5 Concomitant Administration with Strong or Moderate CYP3A Inducers Avoid concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A, which may lead to loss of efficacy of NURTEC ODT [see Drug Interactions (7.2) , Clinical Pharmacology (12.3) ] .
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Rimegepant side effects
▾
Most people tolerate it well. The common side effects are:
Common side effects
- Nausea
- Stomach pain or indigestion (abdominal pain/dyspepsia), seen when used for prevention
When to get medical help
- Get emergency help for signs of a serious allergic reaction, such as trouble breathing, a severe rash or swelling. These can happen days after a dose.
- Call your doctor if you notice new or worsening high blood pressure.
- Call your doctor if your fingers or toes develop color changes or painful symptoms that may signal Raynaud’s phenomenon. Stop the medicine and get evaluated if this happens.
- Call your doctor if you have an unusual or severe reaction after taking it.
Rimegepant warnings and precautions
▾
- Serious allergic reactions: anaphylaxis, trouble breathing and rash can occur, even days after a dose. Stop the medicine and get treated.
- High blood pressure: new or worsening cases have been reported, most often within 7 days of starting. Some people needed medication or hospital care.
- Raynaud’s phenomenon: new or worsening cases have occurred, sometimes with serious pain, hospitalization or disability. Stop the medicine if symptoms develop.
Rimegepant interactions
▾
Some medicines change how much rimegepant is in your body.
- Strong CYP3A4 inhibitors: avoid, since they raise rimegepant levels significantly.
- Moderate CYP3A4 inhibitors: avoid another dose within 48 hours, since levels may rise.
- Strong or moderate CYP3A inducers: avoid, since they can make it stop working.
- Potent P-gp inhibitors (such as amiodarone, cyclosporine, lapatinib, quinidine, ranolazine): avoid another dose within 48 hours.
Interactions listed in the FDA-approved label
From the Rimegepant prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A4 inhibitors: Concomitant administration results in a significant increase in rimegepant exposure. Avoid concomitant administration.
- Moderate CYP3A4 inhibitors: Concomitant administration may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when concomitantly administered.
- Strong or moderate CYP3A inducers: Concomitant administration can result in a significant reduction in rimegepant exposure, which may lead to loss of efficacy of NURTEC ODT. Avoid concomitant administration.
- Potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine): Concomitant administration may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when concomitantly administered.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Strong CYP3A4 Inhibitors: Avoid concomitant administration. ( 7.1 ) • Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor. ( 7.1 ) • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. ( 7.2 ) • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. ( 7.3 ) 7.1 CYP3A4 Inhibitors Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 [see Clinical Pharmacology (12.3) ] . Concomitant administration of NURTEC ODT with moderate inhibitors of CYP3A4 may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 [see Clinical Pharmacology (12.3) ] . 7.2 CYP3A Inducers Concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A can result in a significant reduction in rimegepant exposure, which may lead to loss of efficacy of NURTEC ODT. Avoid concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A [see Clinical Pharmacology (12.3) ] . 7.3 P-gp Inhibitors Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with potent inhibitors of P-gp [see Clinical Pharmacology (12.3) ] .
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Rimegepant
▾
- Don't use it if you've had a hypersensitivity reaction to rimegepant or its ingredients.
- Tell your prescriber about high blood pressure or Raynaud’s phenomenon.
- Avoid in severe liver impairment (Child-Pugh C).
- It has not been studied in end-stage kidney disease.
- Pregnancy: there are no adequate human data. A pregnancy exposure registry is available.
- Breastfeeding: only a small amount passes into milk, but there are no data on effects on a breastfed infant.
Rimegepant overdose
▾
There is limited experience with overdose. Treatment is supportive care, including monitoring vital signs and how the person is doing. There is no specific antidote, and dialysis is unlikely to remove it.
What Rimegepant does in the body
▾
The link between rimegepant's activity in the body and how it relieves migraine is not known. When taken with sumatriptan, no clinically relevant difference in resting blood pressure was seen versus sumatriptan alone in healthy volunteers. At 4 times the recommended dose, it did not prolong the QT interval (a heart rhythm measure) to any clinically relevant extent.
How your body processes Rimegepant
▾
After Nurtec ODT is taken by mouth, blood levels peak at about 1.5 hours. About 64% is absorbed. Food can delay and lower peak levels, but the studies allowed dosing with or without food.
The body breaks it down mainly through CYP3A4 and, to a lesser extent, CYP2C9. The half-life is about 11 hours. It leaves the body mostly in feces, with some in urine.
Levels were about 40% higher in moderate kidney impairment. Exposure is significantly higher in severe liver impairment.
How to store Rimegepant
▾
Store NURTEC ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Rimegepant
144 supplements and herbal products have documented interactions with Rimegepant in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 103
- Minor · 38
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Rimegepant: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Rimegepant — the kind of thing our pharmacy team would talk through with you at the counter.
What is rimegepant for?
▾
How do I take Nurtec ODT?
▾
What side effects should I expect?
▾
When should I call my doctor or get help?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Rimegepant available over the counter?
▾
When was Rimegepant first available?
▾
Who makes Rimegepant?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Rimegepant on HelloPharmacist
Rimegepant forms and strengths (how it comes)
Rimegepant is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Orally disintegrating tablet
How this form is used
- Nurtec ODT is used for acute treatment of migraine with or without aura in adults.
- Nurtec ODT is used for preventive treatment of episodic migraine in adults.
- Nurtec ODT can be taken with or without food.
- Open Nurtec ODT blister packs with dry hands and peel back the foil. Don't push the tablet through it.
- Place the Nurtec ODT tablet on or under the tongue right after opening. It dissolves without liquid.
- Don't store Nurtec ODT outside the blister pack for later use.
Rimegepant on the U.S. market: products, makers and brands
How Rimegepant appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
2 companies list 3 Rimegepant product records with the FDA, mostly as orally disintegrating tablet; the earliest marketing or approval year on record is 2017. Brand names on the directory include Nurtec Odt, Nurtec; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (12) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Rimegepant is used (Medicaid data)
A general measure of how commonly Rimegepant is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Rimegepant is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Rimegepant prescribed? Of the 1,601 medications we measure, Rimegepant ranks #264 by Medicaid prescriptions — more than 84% of them.
Utilization by Rimegepant product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
rimegepant 75 MG Disintegrating Oral Tablet
Summed across the 1 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2282313
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Rimegepant, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 10 listed Rimegepant NDCs with Medicaid activity.
Compare Rimegepant products
A representative set of FDA-listed product records for Rimegepant — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Orally disintegrating tablet | ||||
| 75 mg | Oral | Pfizer Laboratories Div Pfizer Inc × 2 listings | NDA | View NDC → |
| 75 mg | Oral | Sportpharm LLC | NDA | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Rimegepant NDCs →
Rimegepant side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Rimegepant — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Rimegepant in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Rimegepant FDA approval history
How Rimegepant went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Rimegepant recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Rimegepant recalls since July 2021.
✅No Rimegepant recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2282307 1 dose form · 1 strength
-
Dose form (SCDF) Disintegrating Oral Tablet RxCUI 2618951No current FDA listingClinical drug / strength (SCD) 75 MGRxCUI 2282313
Look up RxCUI 2282307 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Rimegepant supply and shortage status
Whether Rimegepant is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Rimegepant costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Orally Disintegrating · Oral | 75 mg | $128.67 per tablet | NDC details & price history |
| Tablet, Orally Disintegrating · Oral | 75 mg/75 mg | $128.67 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Rimegepant brand names
Rimegepant is sold under 2 brand names in the FDA directory — Nurtec Odt, Nurtec. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Rimegepant: manufacturers and labelers
2 companies list Rimegepant products with the FDA. By number of product records, the largest are Pfizer Laboratories Div Pfizer Inc, Sportpharm LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Rimegepant drug class (RxNorm)
Rimegepant belongs to the Calcitonin Gene-related Peptide Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Rimegepant page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Pfizer Laboratories Div Pfizer Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →